INTELLIA THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
INTELLIA THERAPEUTICS, INC. (NTLA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 4.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26
- INTELLIA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was 4.50%, a 125.00% increase from fiscal 2024.
- INTELLIA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 2.00%, a 25.00% increase from fiscal 2023.
- INTELLIA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 1.60%.
- INTELLIA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -0.10%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | 4.50% 10-K · filed 2026-02-26 |
| 2024-12-31 | 2.00% 10-K · filed 2026-02-26 |
| 2023-12-31 | 1.60% 10-K · filed 2026-02-26 |
| 2022-12-31 | -0.10% 10-K · filed 2025-02-27 |
| 2021-12-31 | -16.80% 10-K · filed 2024-02-22 |
| 2020-12-31 | -1.30% 10-K · filed 2023-02-23 |
| 2019-12-31 | 1.20% 10-K · filed 2022-02-24 |
| 2018-12-31 | -0.60% 10-K · filed 2021-02-26 |
| 2017-12-31 | 3.60% 10-K · filed 2020-02-27 |
| 2016-12-31 | 1.90% 10-K · filed 2019-02-27 |
| 2015-12-31 | 1.10% 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |